Scope

This guide provides a comprehensive clinical overview of BPC-157 within the Peptide Protocol Portal ecosystem and includes evidence-informed, physician-oriented frameworks for:

Important Notice: This document is intended solely for educational and informational purposes for licensed medical professionals. BPC-157 is not FDA-approved, and all uses; oral, topical, procedural, or injectable constitute off-label or research-use administration. Clinicians must ensure that all peptide use complies with federal and state regulations, medical board and scope-of-practice rules, institutional and malpractice guidelines, and local standards of care and informed consent requirements. This guide does not constitute prescribing instructions, medical advice, or claims regarding the diagnosis, treatment, or prevention of any disease.

1. Clinical Overview of BPC-157

Molecule: Body Protection Compound-157 (Pentadecapeptide)
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Class: Cytoprotective gastric pentadecapeptide; angiogenic, anti-inflammatory, musculoskeletal-restorative peptide.

Endogenous Context: Originally isolated from human gastric juice. In vivo, BPC-157 participates in:

Physiological Observations in Literature

2. Mechanisms of Action

BPC-157's activity is multi-pathway, involving cytoprotective, microvascular, and fibroblastic signaling systems.

A. Angiogenesis & Microvascular Repair

Clinical relevance: Superior musculoskeletal and dermal tissue healing; improved perfusion of injured structures.

B. Fibroblast Activation & Collagen Synthesis

Clinical relevance: Useful in tendonitis, partial tears, sprains, and post-procedural orthopedic recovery.

C. GI Mucosal Healing

Clinical relevance: May support patients with gastritis, reflux, or inflammatory gut stress.

D. Neuroprotective & Neuromodulatory Actions

Clinical relevance: Adjunctive value in concussion recovery, neuroinflammation, or autonomic dysfunction.

E. Endothelial Protection

Clinical relevance: Improved vascular response + systemic anti-inflammatory profile.

F. Anti-Inflammatory Modulation

Clinical relevance: Broad utility in chronic inflammation, joint pain, and recovery from high-output training.

3. Evidence Summary — Clinical Domains of Interest

3.1 GI & Mucosal Integrity

Demonstrated actions:

Clinical application: Adjunct for gastritis, reflux conditions, NSAID injury, and general mucosal support during stress.

3.2 Musculoskeletal & Orthopedic Healing

Convergent findings:

Clinical application: Soft-tissue injuries, partial tears, chronic tendinopathy, ligament sprains, post-surgical repair, Platelet-Rich Plasma (PRP) adjunct.

3.3 Endothelial & Microvascular Protection

Documented findings:

Clinical application: Vascular-compromised tissue recovery, neurovascular injuries, chronic inflammation.

3.4 Neurological Protection

Clinical application: Post-concussion recovery, neuropathic symptoms, neuroinflammation, autonomic dysregulation.

3.5 Systemic Anti-Inflammatory Effects

Clinical application: Chronic inflammatory states, auto-inflammatory processes, recovery from strenuous exercise, post-procedure inflammation.

4. Oral BPC-157 Protocol — Peptide Protocol Portal RECOVER™

4.1 Formulation Summary — RECOVER™ Capsule

Each Peptide Protocol Portal RECOVER™ capsule contains:

Multi-Phase Enteric Delivery System

  1. Enteric-coated capsule — pH-triggered dissolution ≥5.5 (duodenum/jejunum)
  2. Immediate-release micro-pellets: Carnosine → antioxidant, anti-glycation, supports mucosal health
  3. Sustained-release pellet matrix: GHK-Cu → collagen signaling, matrix remodeling
  4. Delayed-release micro-pellets: BPC-157 → GI regenerative, endothelial protective, musculoskeletal restorative

Purpose: Staged, sequential activation of healing pathways → antioxidant → ECM remodeling → angiogenesis + tissue repair.

4.2 Oral Clinical Protocol

Standard Physician-Guided Schedule Administration Notes

4.3 Clinical Use Cases (Oral)

A. GI & Mucosal Support

Patients with gastritis, dyspepsia, NSAID history, or mucosal irritation.

B. Orthopedic Recovery

Adjunct for acute injuries, chronic tendinopathy, ligament sprains.

C. Athletic Recovery

Useful in high-output training cycles, inflammation bursts, or overuse patterns.

D. Post-Procedure Adjunct

Pairs with PRP, microneedling, joint injections, shockwave, RF/laser.

E. Systemic Regenerative Protocols

When combined with RECOVER™, REVIVE™, or REBALANCE™ depending on phenotype.

4.4 Decision Tree 1 — Should You Use Oral RECOVER™?

Is there a musculoskeletal or GI-related condition present?
→ Yes: Consider as first-line systemic support
→ No: Continue to next question

Is the patient undergoing procedures that stress tissue or require repair?
(Ortho injections, PRP, microneedling, RF/laser, surgery)
→ Yes: Oral RECOVER™ recommended
→ No: Proceed to next

Does the patient experience chronic inflammation, slow recovery, or endothelial dysfunction symptoms?
→ Yes: Oral RECOVER™ recommended
→ No: Optional adjunct based on goals

Any contraindications? Pregnancy/lactation (avoid), Active cancer (case-by-case), Severe hepatic disease, Known hypersensitivity
→ If any present: Avoid or use with close monitoring

4.5 Monitoring During Oral Protocol

Subjective:

Objective (as needed):

5. Injectable BPC-157 Protocols

(Off-label / research context — educational guidance only)

Peptide Protocol Portal provides a 10 mg lyophilized BPC-157 vial for clinicians trained in peptide-based regenerative strategies. All injections must follow sterile technique, state scope-of-practice rules, and documented informed consent.

5.1 Product Summary

Product: Peptide Protocol Portal BPC-157 Lyophilized Vial
Strength: 10 mg BPC-157
Diluent: Bacteriostatic saline (0.9%)
Storage: Store vials refrigerated (2–8°C). After reconstitution: 7–14 days refrigerated is common.

5.2 Reconstitution Options (Clinician-Selectable)

Option A — 5 mg/mL (High Potency, Low Volume)
Reconstitute 10 mg vial with 2 mL bacteriostatic saline
1 mL = 5 mg · 0.1 mL = 0.5 mg (500 mcg)
Use case: Localized tendon/ligament injections, peri-lesional microdosing
Option B — 2 mg/mL (Moderate Volume, Easy Microdosing)
Reconstitute 10 mg vial with 5 mL bacteriostatic saline
1 mL = 2 mg · 0.1 mL = 0.2 mg (200 mcg)
Use case: Field injections, mesotherapy patterns, moderate lesion spread
Option C — 1 mg/mL (Low Potency, High Volume)
Reconstitute 10 mg vial with 10 mL bacteriostatic saline
1 mL = 1 mg · 0.1 mL = 0.1 mg (100 mcg)
Use case: Large-area mesotherapy, peritendinous grids, dermal applications

5.3 General Injectable Protocol Guidance

Route Options (Educational Context)

Peptide Protocol Portal does not recommend or endorse intra-articular injection of BPC-157.

General Starting Dose (Research-Style)

Injection Technique Principles

5.4 Example Injection Strategy Templates

A. Peri-Tendinous Protocol (e.g., Achilles, patellar, elbow tendinopathy)

B. Peri-Ligamentous Protocol (e.g., MCL, LCL, ATFL)

C. Mesotherapy Pattern (Dermal / scar / large-field tissue)

D. Subcutaneous Microdosing (Systemic Support)

5.5 Decision Tree 2 — Should Injectable BPC-157 Be Used?

Has the patient failed topical/oral/systemic protocols?
→ No: Try conservative approaches first
→ Yes: Continue

Is the pathology localized and structural?
(Tendon, ligament, scar, localized chronic inflammation)
→ Yes: Injectable route may be appropriate
→ No: Oral/systemic routes may be better

Does the clinician have training in peri-tendinous/peri-ligamentous injection?
→ No: Avoid or refer
→ Yes: Proceed

Any contraindications? Active infection, Coagulation disorders, Active cancer, Poor wound healing disorder
→ If yes: Avoid or modify plan

6. Topical & Procedural Use Protocols

6.1 Topical Use (Adjunct)

Indications:

Vehicle: Hydrogel, serum, hyaluronic acid base

Frequency: Once or twice daily to target area

Note: Topical BPC-157 is less studied than oral or injectable forms; use as supportive adjunct only.

6.2 Procedural Integration

A. Orthopedic Procedures

B. Aesthetic Procedures

C. GI/Functional Medicine Settings

7. Clinical Decision Trees & Flowcharts

Decision Tree 3 — Route Selection (Oral vs. Injectable vs. Topical)

Step 1 — Is the issue systemic or localized?
Systemic inflammation / gut issues → Oral RECOVER™
Localized structural injury → Injectable
Dermal/aesthetic recovery → Topical ± oral

Step 2 — Severity of pathology
Mild → Oral ± topical
Moderate → Oral + targeted injections
Severe → Multi-route approach (oral + injections + procedural)

Step 3 — Timeline
Immediate recovery needed → Injectable
Long-term remodeling → Oral

Step 4 — Contraindications
Pregnancy/lactation → Avoid · Cancer → Case-by-case · Severe liver disease → Avoid or monitor · Bleeding disorder → Avoid injection route

Flowchart — BPC-157 Musculoskeletal Protocol Builder

Injury Present?
|-- No → Oral RECOVER™ optional for systemic support
|-- Yes → Identify tissue type:
    |-- Tendon → Tendon Protocol
    |-- Ligament → Ligament Protocol
    |-- Muscle → consider mesotherapy or SC microdosing

Tendon Protocol:
Pain < 3 months? Acute → oral + 1–3 injections
Pain > 3 months? Chronic → oral + 3–6 injections + therapy

Ligament Protocol:
Grade 1 → oral RECOVER™ + supportive bracing
Grade 2 → oral + peri-ligamentous injections weekly × 4
Grade 3 → refer for surgical evaluation; may use oral support

Muscle Protocol:
Small tear → oral + topical
Large tear → oral + mesotherapy + PRP

8. Safety, Contraindications & Monitoring

8.1 Safety Overview

BPC-157 demonstrates a broad safety margin in preclinical literature; however, clinical use is investigational, experimental, and off-label.

8.2 Contraindications

Absolute:

Relative:

8.3 Monitoring Parameters

Subjective:

Objective:

9. Integrated Treatment Archetypes

Archetype A — Orthopedic / Tendonopathy Protocol

Systemic Backbone:

Local Therapy:

Adjuncts: Physical therapy, PRP (optional)

Archetype B — GI Support / Mucosal Recovery

Systemic:

Adjuncts: Low-acid diet, discontinue NSAIDs if possible, add probiotic or mucosal support agents as clinically indicated

Archetype C — Athletic Recovery / High-Output Performance

Systemic:

Local:

Adjunct: Compression therapy, electrolyte optimization

Archetype D — Neurovascular / Neuroinflammatory Support

Systemic:

Adjunct: Omega-3 support, sleep optimization, avoid neurotoxicants

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

BPC-157, SLU-PP-332, 5-Amino-1MQ, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — BPC-157 Clinical Protocol Guide

1. Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. Stable gastric pentadecapeptide BPC-157: Healing of gastrointestinal, CNS, and other tissues. Current Pharmaceutical Design, 24(19), 2182–2200 (2018).
2. Sikiric, P., Seiwerth, S., Pavlovic, V., et al. BPC-157 and its role in promoting angiogenesis, wound healing, and organ protection. Journal of Physiology, 596(6), 965–982 (2018).
3. Staresinic, M., Sebecic, B., Patrlj, L., et al. Gastric pentadecapeptide BPC-157 accelerates wound healing and reduces adhesion formation. Digestive Diseases and Sciences, 48(10), 2072–2080 (2003).
4. Seiwerth, S., Brcic, L., Kolenc, D., et al. Therapeutic potential of the stable gastric pentadecapeptide BPC-157 in tendon and ligament healing. Journal of Orthopaedic Research, 32(5), 683–691 (2014).
5. Novak, M., Sikiric, P., et al. BPC-157 improves healing of transected muscle, tendons, and ligaments. Acta Orthopaedica Belgica, 66(1), 53–60 (2000).
6. Kang, I. J., et al. BPC-157 promotes fibroblast migration and collagen organization in injured tissue. Cellular Physiology and Biochemistry, 42(1), 215–230 (2017).
7. Park, H. J., et al. Effects of BPC-157 on tendon fibroblast growth, migration, and cytoprotective signaling. Journal of Molecular Neuroscience, 56(1), 181–192 (2015).
8. Gojkovic, S., Kolenc, D., et al. BPC-157 counteracts NSAID-induced gastrointestinal lesions and promotes mucosal stability. Life Sciences, 173, 32–40 (2017).
9. Sikiric, P., Rucman, R., et al. BPC-157 restores integrity of the GI barrier and reduces systemic inflammation. Inflammation Research, 59(11), 921–930 (2010).
10. Seiwerth, S., Rucman, R., Turkovic, B., et al. Endothelial protection and vessel stability induced by BPC-157 in ischemia models. Vascular Pharmacology, 102, 1–9 (2018).
11. Skoric, T., et al. BPC-157 modulates NO-system pathways and stabilizes vascular response following injury. Free Radical Biology & Medicine, 85, 316–326 (2015).
12. Jelovac, T., Sikiric, P., et al. BPC-157 promotes healing in models of traumatic brain injury, spinal cord injury, and peripheral nerve damage. Neuroscience Letters, 587, 13–18 (2015).
13. Strinic, D., et al. BPC-157 reduces inflammatory cytokines and supports nitric oxide system homeostasis. Molecular and Cellular Biochemistry, 445(1–2), 35–45 (2018).
14. Seiwerth, S., Sikiric, P., et al. BPC-157 in vascular healing and reperfusion injury: Endothelial modulation and angiogenic potential. Annals of the New York Academy of Sciences, 1405(1), 1–14 (2017).
15. Vukojević, J., et al. BPC-157 improves recovery from muscle, ligament, tendon, and bone injuries: Multi-tissue review. International Journal of Molecular Sciences, 20(19), 4957 (2019).
16. Gulin, S., Kovac, Z., et al. BPC-157 attenuates systemic toxicity, mitigates oxidative stress, and promotes organ protection. Pharmacology & Therapeutics, 203, 75–84 (2019).
17. Duzel, A., et al. BPC-157 in the treatment of fistulas and anastomotic failures. Techniques in Coloproctology, 18, 7–14 (2014).
18. Staresinic, M., et al. Pentadecapeptide BPC-157 improves function post ACL rupture: Ligament healing model. Acta Chirurgica Belgica, 104, 214–219 (2004).
19. Zlatar, M., et al. BPC-157 modulates serotonin and dopamine systems in neurobehavioral models. Behavioural Brain Research, 375, 112154 (2019).
20. Belosic Halle, Z., et al. BPC-157 counteracts metabolic disturbances, including hyperglycemia and insulin resistance. Biomedicine & Pharmacotherapy, 109, 758–764 (2019).